Business Description
TSH Biopharm Corp Ltd
NAICS : 325412
SIC : 2834
ISIN : TW0008432006
Description
TSH Biopharm Corp Ltd is engaged in the sale of a variety of pharmaceuticals, chemical drugs and biotechnology services. The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.13 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.13 | |||||
| Interest Coverage | 376.5 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.2 | |||||
| Beneish M-Score | -0.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.9 | |||||
| 3-Year EBITDA Growth Rate | 4.6 | |||||
| 3-Year EPS without NRI Growth Rate | -0.6 | |||||
| 3-Year FCF Growth Rate | 45.4 | |||||
| 3-Year Book Growth Rate | -0.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.25 | |||||
| 9-Day RSI | 44.05 | |||||
| 14-Day RSI | 47.51 | |||||
| 6-1 Month Momentum % | 5.82 | |||||
| 12-1 Month Momentum % | 28.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | |||||
| Quick Ratio | 4.45 | |||||
| Cash Ratio | 3.02 | |||||
| Days Inventory | 95.76 | |||||
| Days Sales Outstanding | 64.48 | |||||
| Days Payable | 40.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.97 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | -3.9 | |||||
| Forward Dividend Yield % | 1.97 | |||||
| 5-Year Yield-on-Cost % | 1.58 | |||||
| Shareholder Yield % | 2.18 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.3 | |||||
| Operating Margin % | 15.19 | |||||
| Net Margin % | 11.39 | |||||
| FCF Margin % | 11.65 | |||||
| ROE % | 9.69 | |||||
| ROA % | 7.73 | |||||
| ROIC % | 22.49 | |||||
| ROC (Joel Greenblatt) % | 75.59 | |||||
| ROCE % | 12.2 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.35 | |||||
| PE Ratio without NRI | 20.14 | |||||
| Shiller PE Ratio | 26.56 | |||||
| Price-to-Owner-Earnings | 27.27 | |||||
| PEG Ratio | 5.92 | |||||
| PS Ratio | 2.32 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| Price-to-Free-Cash-Flow | 19.87 | |||||
| Price-to-Operating-Cash-Flow | 19.44 | |||||
| EV-to-EBIT | 9.74 | |||||
| EV-to-EBITDA | 8.38 | |||||
| EV-to-Revenue | 1.57 | |||||
| EV-to-FCF | 13.76 | |||||
| Price-to-Projected-FCF | 1.28 | |||||
| Price-to-Median-PS-Value | 0.47 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.71 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 2.81 | |||||
| Price-to-Net-Cash | 7.89 | |||||
| Earnings Yield (Greenblatt) % | 10.26 | |||||
| FCF Yield % | 5.03 | |||||
| Forward Rate of Return (Yacktman) % | 9.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TSH Biopharm Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,050.973 | ||
| EPS (TTM) (NT$) | 3.1 | ||
| Beta | 0.49 | ||
| Volatility % | 35.68 | ||
| 14-Day RSI | 47.51 | ||
| 14-Day ATR (NT$) | 1.672934 | ||
| 20-Day SMA (NT$) | 64.055 | ||
| 12-1 Month Momentum % | 28.94 | ||
| 52-Week Range (NT$) | 48.25 - 71.1 | ||
| Shares Outstanding (Mil) | 38.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TSH Biopharm Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TSH Biopharm Corp Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TSH Biopharm Corp Ltd Frequently Asked Questions
What is TSH Biopharm Corp Ltd(ROCO:8432)'s stock price today?
The current price of ROCO:8432 is NT$63.30. The 52 week high of ROCO:8432 is NT$71.10 and 52 week low is NT$48.25.
When is next earnings date of TSH Biopharm Corp Ltd(ROCO:8432)?
The next earnings date of TSH Biopharm Corp Ltd(ROCO:8432) is .
Does TSH Biopharm Corp Ltd(ROCO:8432) pay dividends? If so, how much?
The Dividend Yield %  of TSH Biopharm Corp Ltd(ROCO:8432) is 1.97% (As of Today), Highest Dividend Payout Ratio of TSH Biopharm Corp Ltd(ROCO:8432) was 1.83. The lowest was 0.41. And the median was 1.07. The  Forward Dividend Yield % of TSH Biopharm Corp Ltd(ROCO:8432) is 1.97%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers